Breaking News

Glenmark Launches Latanoprost Ophthalmic Solution

The product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution, 0.005%.

Author Image

By: Charlie Sternberg

Associate Editor

Glenmark Pharmaceuticals Inc. USA has launched Latanoprost Ophthalmic Solution, a 0.005% (0.05 mg/mL) ophthalmic solution. This product is bioequivalent and therapeutically equivalent to the reference listed drug, Xalatan Ophthalmic Solution. Marc Kikuchi, President & Business Head, North America, expressed excitement about the launch, stating that it marks the fourth ophthalmic product in Glenmark’s portfolio. “This addition highlights our commitment to meeting market needs and provid...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters